SG Americas Securities LLC Has $147,000 Stock Position in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)

SG Americas Securities LLC increased its stake in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) by 17.5% during the fourth quarter, Holdings Channel.com reports. The fund owned 21,559 shares of the company’s stock after buying an additional 3,210 shares during the period. SG Americas Securities LLC’s holdings in Y-mAbs Therapeutics were worth $147,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Tower Research Capital LLC TRC lifted its stake in shares of Y-mAbs Therapeutics by 924.1% in the first quarter. Tower Research Capital LLC TRC now owns 5,899 shares of the company’s stock worth $30,000 after acquiring an additional 5,323 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in Y-mAbs Therapeutics by 248.7% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,513 shares of the company’s stock valued at $99,000 after buying an additional 4,645 shares during the period. BNP Paribas Arbitrage SA lifted its stake in Y-mAbs Therapeutics by 172.5% in the second quarter. BNP Paribas Arbitrage SA now owns 7,980 shares of the company’s stock valued at $121,000 after buying an additional 5,052 shares during the period. Principal Financial Group Inc. acquired a new position in Y-mAbs Therapeutics in the second quarter valued at approximately $160,000. Finally, Russell Investments Group Ltd. lifted its stake in Y-mAbs Therapeutics by 1,347.5% in the first quarter. Russell Investments Group Ltd. now owns 11,812 shares of the company’s stock valued at $59,000 after buying an additional 10,996 shares during the period. 70.85% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, SVP Vignesh Rajah sold 1,711 shares of the company’s stock in a transaction on Tuesday, March 5th. The stock was sold at an average price of $16.53, for a total transaction of $28,282.83. Following the completion of the sale, the senior vice president now owns 33,889 shares in the company, valued at $560,185.17. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 21.50% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on YMAB. HC Wainwright boosted their price target on Y-mAbs Therapeutics from $21.00 to $22.00 and gave the company a “buy” rating in a research note on Wednesday, March 6th. BMO Capital Markets boosted their price target on Y-mAbs Therapeutics from $16.00 to $26.00 and gave the company an “outperform” rating in a research note on Monday, March 4th. Wedbush reissued an “outperform” rating and issued a $18.00 price target (up from $12.00) on shares of Y-mAbs Therapeutics in a research note on Monday, February 12th. Finally, Canaccord Genuity Group boosted their price target on Y-mAbs Therapeutics from $22.00 to $26.00 and gave the company a “buy” rating in a research note on Monday, March 4th. Two research analysts have rated the stock with a sell rating and four have given a buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $16.57.

Y-mAbs Therapeutics Stock Up 1.5 %

Shares of NASDAQ:YMAB opened at $15.14 on Wednesday. Y-mAbs Therapeutics, Inc. has a twelve month low of $4.60 and a twelve month high of $20.90. The stock’s 50 day moving average is $15.64 and its 200-day moving average is $10.02. The firm has a market capitalization of $662.83 million, a price-to-earnings ratio of -30.90 and a beta of 0.74.

Y-mAbs Therapeutics (NASDAQ:YMAB) last issued its earnings results on Thursday, February 29th. The company reported ($0.02) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.17. Y-mAbs Therapeutics had a negative return on equity of 20.72% and a negative net margin of 25.26%. The company had revenue of $23.36 million for the quarter, compared to analyst estimates of $21.72 million. Equities research analysts anticipate that Y-mAbs Therapeutics, Inc. will post -0.43 earnings per share for the current fiscal year.

About Y-mAbs Therapeutics

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.